Trial record 3 of 8 for:
Apraglutide
Proof-of-concept Trial of Apraglutide in GVHD
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05415410 |
Recruitment Status :
Active, not recruiting
First Posted : June 13, 2022
Last Update Posted : January 9, 2024
|
Sponsor:
VectivBio AG
Information provided by (Responsible Party):
VectivBio AG
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | February 8, 2022 | ||||
First Posted Date ICMJE | June 13, 2022 | ||||
Last Update Posted Date | January 9, 2024 | ||||
Actual Study Start Date ICMJE | May 25, 2022 | ||||
Estimated Primary Completion Date | August 30, 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Proof-of-concept Trial of Apraglutide in GVHD | ||||
Official Title ICMJE | A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy | ||||
Brief Summary | The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal acute graft versus host disease (aGVHD). | ||||
Detailed Description | This is an international, multicenter, randomized proof-of-concept trial to evaluate safety, tolerability, efficacy, durability of response, and clinical outcomes of apraglutide administration to subjects with steroid-refractory (SR) aGVHD of the lower GI tract being treated with systemic steroids (SS) and ruxolitinib (RUX). | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment |
||||
Condition ICMJE | GVHD | ||||
Intervention ICMJE | Drug: Apraglutide
Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Actual Enrollment ICMJE |
31 | ||||
Original Estimated Enrollment ICMJE |
34 | ||||
Estimated Study Completion Date ICMJE | August 30, 2025 | ||||
Estimated Primary Completion Date | August 30, 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 12 Years and older (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Germany, Portugal, Spain, United States | ||||
Removed Location Countries | Italy | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT05415410 | ||||
Other Study ID Numbers ICMJE | TA799-101 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Current Responsible Party | VectivBio AG | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | VectivBio AG | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | VectivBio AG | ||||
Verification Date | January 2024 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |